Why Vaxart Stock Is Crushing It Today
Shares of Vaxart (NASDAQ: VXRT) were soaring 20.8% as of 11:22 a.m. EDT on Monday. The huge jump came after the biotech announced Food and Drug Administration clearance to begin a phase 1 clinical trial for Vaxart's oral coronavirus vaccine candidate.
Vaxart reported promising pre-clinical results for its oral COVID-19 vaccine candidate in April. But investors really want to see how the investigational vaccine will work in humans. Thanks to the FDA clearance, they're about to get that opportunity.
Image source: Getty Images.
Source Fool.com